{"protocolSection":{"identificationModule":{"nctId":"NCT05965687","orgStudyIdInfo":{"id":"OPENS-3"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)","officialTitle":"Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-08-17","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-08-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-10-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-06-07","studyFirstSubmitQcDate":"2023-07-20","studyFirstPostDateStruct":{"date":"2023-07-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-06","lastUpdatePostDateStruct":{"date":"2023-11-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Ji Xunming,MD,PhD","investigatorTitle":"Professor","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Ji Xunming,MD,PhD","class":"OTHER"},"collaborators":[{"name":"Beijing Friendship Hospital","class":"OTHER"},{"name":"Beijing Shijitan Hospital, Capital Medical University","class":"OTHER"},{"name":"Beijing Tongren Hospital","class":"OTHER"},{"name":"People's Hospital of Beijing Daxing District","class":"OTHER"},{"name":"Tianjin Huanhu Hospital","class":"OTHER"},{"name":"Guizhou Provincial People's Hospital","class":"OTHER"},{"name":"Shandong Provincial Hospital","class":"OTHER_GOV"},{"name":"The First Affiliated Hospital of Soochow University","class":"OTHER"},{"name":"The First Affiliated Hospital of Zhengzhou University","class":"OTHER"},{"name":"The Affiliated Hospital of Xuzhou Medical University","class":"OTHER"},{"name":"Jining First People's Hospital","class":"OTHER"},{"name":"Linyi People's Hospital","class":"OTHER"},{"name":"Nanyang Central Hospital","class":"OTHER"},{"name":"Rizhao People's Hospital","class":"OTHER"},{"name":"Zhumadian Central Hospital","class":"OTHER"},{"name":"Second Affiliated Hospital of Nanchang University","class":"OTHER"},{"name":"Affiliated Hospital of Nantong University","class":"OTHER"},{"name":"The Second Hospital of Anhui Medical University","class":"OTHER"},{"name":"Changsha Central Hospital","class":"OTHER"},{"name":"Jiujiang University Affiliated Hospital","class":"OTHER_GOV"},{"name":"Liaocheng People's Hospital","class":"OTHER"},{"name":"Chengde Central Hospital","class":"OTHER_GOV"},{"name":"The First Affiliated Hospital of Anhui Medical University","class":"OTHER"},{"name":"Jiangxi Provincial People's Hopital","class":"OTHER"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the efficacy and safety of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke.","detailedDescription":"In this study, cases of acute ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from onset are included. The Normobaric Hyperoxia(NBO) group receive basic intravenous thrombolysis and given 100% oxygen inhalation at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. The control group receive basic intravenous thrombolysis and given oxygen inhalation at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. The investigators aimed to determine the efficacy and safety of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2218,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NBO group","type":"EXPERIMENTAL","description":"Normobaric Hyperoxia combined with intravenous thrombolysis","interventionNames":["Procedure: Normobaric Hyperoxia","Drug: Intravenous thrombolysis(rt-PA)"]},{"label":"Control group","type":"PLACEBO_COMPARATOR","description":"Nasal oxygen combined with intravenous thrombolysis","interventionNames":["Procedure: Nasal oxygen","Drug: Intravenous thrombolysis(rt-PA)"]}],"interventions":[{"type":"PROCEDURE","name":"Normobaric Hyperoxia","description":"Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.","armGroupLabels":["NBO group"]},{"type":"PROCEDURE","name":"Nasal oxygen","description":"For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.","armGroupLabels":["Control group"]},{"type":"DRUG","name":"Intravenous thrombolysis(rt-PA)","description":"10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.","armGroupLabels":["Control group","NBO group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Excellent functional outcome","description":"Proportion of subjects with modified Rankin Scale(mRS) 0-1 at 90±7 days after randomization;mRS score ranges from 0 to 5, and the higher score means a worse outcome","timeFrame":"90±7 days after randomization"}],"secondaryOutcomes":[{"measure":"Cerebral infarct volume","description":"The infarct volume of cerebral infarct is evaluated by MRI","timeFrame":"24-48hours after randomization"},{"measure":"modified rankin scale (mRS) score","description":"Ordinal distribution of mRS at 90±7 days after randomization;mRS score ranges from 0 to 5, and the higher score means a worse outcome","timeFrame":"90±7 days after randomization"},{"measure":"Good functional outcome","description":"Proportion of subjects with modified rankin scale (mRS) 0-2 at 90±7 days after randomization;mRS score ranges from 0 to 5, and the higher score means a worse outcome","timeFrame":"90 ± 7 days after randomization"},{"measure":"Proportion of subjects with modified rankin scale (mRS) 0-3","description":"Proportion of subjects with mRS 0-3 at 90±7 days after randomization;mRS score ranges from 0 to 5, and the higher score means a worse outcome","timeFrame":"90 ± 7 days after randomization"},{"measure":"Scores assessed by National Institutes of Health Stroke Scale(NIHSS)","description":"Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits","timeFrame":"4 ± 2 hours, 24 ± 6 hours, 72 ± 24 hours, 7 ± 2 days after randomization"},{"measure":"The proportion of neurological function improvement","description":"≥ 4 point reduction in National Institutes of Health Stroke Scale (NIHSS) score from baseline at 24 ± 6 hours after randomization;NIHSS score ranges from 0 to 42, and higher scores mean a worse outcome","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Proportion of subjects with modified rankin scale (mRS) 0-1","description":"Proportion of subjects with mRS 0-1 at 30±7 days after randomization;mRS score ranges from 0 to 5, and the higher score means a worse outcome","timeFrame":"30 ± 7 days after randomization"},{"measure":"Barthel Index (BI)","description":"The BI is an ordinal disability score of 10 categories (range from 0 to 100, higher values indicate better prognosis)","timeFrame":"30 ± 7 days,90 ± 7 days after randomization"},{"measure":"EuroQol five dimensions questionnaire（EQ-5D）","description":"The score ranges from 0 to 100, with higher scores indicating optimal health","timeFrame":"baseline before randomization,7 ± 2 days,30 ± 7 days,90 ± 7 days after randomization"},{"measure":"Days of hospitalization","description":"Length of stay in hospital","timeFrame":"30 ± 7 days after randomization"},{"measure":"Stroke-related mortality","description":"Safety endpoint; the proportion of stroke related deaths in each group","timeFrame":"90 ± 7 days after randomization"},{"measure":"All-cause mortality","description":"Safety endpoint; the proportion of all patients who died in each group","timeFrame":"90 ± 7 days after randomization"},{"measure":"Symptomatic intracranial hemorrhage","description":"Proportion of subjects with symptomatic intracranial hemorrhage at 24 ± 6 hours after randomization (defined by ECASSII and ECASS III)","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Asymptomatic intracranial hemorrhage","description":"The incidence of asymptomatic intracranial hemorrhage at 24 ± 6 hours after randomization","timeFrame":"24 ± 6 hours after randomization"},{"measure":"PH2 intracranial hemorrhage","description":"The incidence of PH2 intracranial hemorrhage at 24 ± 6 hours after randomization (according to SITS standards)","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Any intracranial hemorrhage","description":"The incidence of any intracranial hemorrhage at 24 ± 6 hours after randomization","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Systematic bleeding","description":"The incidence of systematic bleeding at 24 ± 6 hours after randomization","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Early neurological deterioration","description":"Safety endpoint; defined as ≥4 point increase in National Institutes of Health Stroke Scale (NIHSS) score from baseline;NIHSS score ranges from 0 to 42, and higher scores mean a worse outcome","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Oxygen-related adverse events","description":"Safety endpoint; the proportion of oxygen-related adverse events in each group, including severe lung infection, pneumothorax, atelectasis, respiratory failure, acute respiratory distress syndrome, and cardiopulmonary arrest","timeFrame":"90 ± 7 days after randomization"},{"measure":"Adverse events/serious adverse events","description":"Safety endpoint; the proportion of adverse events/serious adverse events in each group","timeFrame":"24 ± 12 hours, 7 ± 2 days, 90± 7 days after randomization"},{"measure":"PaO2 of arterial blood gas analysis","description":"Safety endpoint","timeFrame":"after 4 hours of oxygen therapy"},{"measure":"PaCO2 of arterial blood gas analysis","description":"Safety endpoint","timeFrame":"after 4 hours of oxygen therapy"},{"measure":"Potential of hydrogen(PH) of arterial blood gas analysis","description":"Safety endpoint","timeFrame":"after 4 hours of oxygen therapy"},{"measure":"Concentration of Lactic acid of arterial blood gas analysis","description":"Safety endpoint","timeFrame":"after 4 hours of oxygen therapy"},{"measure":"Systolic and diastolic blood pressure","description":"Safety endpoint; vital signs","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Heart rate","description":"Safety endpoint; vital signs","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Respiratory rate","description":"Safety endpoint; vital signs","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Oxygen saturation","description":"Safety endpoint; vital signs","timeFrame":"24 ± 6 hours after randomization"},{"measure":"Unit costs","description":"Unit costs will be attached to resource use, patient-reported and from hospital records after randomization, to obtain a cost per patient over the period of follow-up","timeFrame":"7 ± 2 days, 30 ± 7 days,90 ± 7 days after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age≥18 years;\n2. The time from onset to randomization is within 4.5 hours of onset;\n3. The clinical diagnosis is acute ischemic stroke (the criteria followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018);\n4. Baseline NIHSS (at the time of randomization) should be ≥5 and ≤25 points;\n5. Pre-stroke mRS score≤1 points;\n6. Informed consent from the patient or surrogate.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);\n2. Past history of intracranial hemorrhage;\n3. Rapid neurological function improvement, NIHSS score less than 5 points;\n4. Presence of proximal arterial occlusion on computed tomographic angiography(CTA)/magnetic resonance angiography(MRA) (e.g., intracranial internal carotid artery(ICA), middle cerebral artery(MCA)-M1, and vertebrobasilar arteries);\n5. Massive anterior cerebral infarction identified by CT or MRI (ASPECT \\< 6 or lesions larger than one third of the territory of the middle cerebral artery);\n6. Intended to proceed endovascular treatment;\n7. Pregnant women, or planning to become pregnant during the trial;\n8. A history of severe head trauma or stroke within 3 months;\n9. A history of intracranial or spinal surgery within 3 months;\n10. A history of gastrointestinal or urinary bleeding within 3 weeks;\n11. two weeks of major surgery;\n12. Arterial puncture was performed at the hemostasis site that was not easily compressed within 1 week;\n13. Active visceral bleeding;\n14. Intracranial tumors, large intracranial aneurysms;\n15. Aortic arch dissection was found;\n16. Severe, sustained hypertension (Systolic Blood Pressure \\>185 mmHg or Diastolic Blood Pressure \\>110 mmHg);\n17. Baseline blood glucose of \\<50mg/dL (2.78 mmol) or \\>400mg/dL (22.20 mmol);\n18. Oral warfarin anticoagulant with international normalized ratio(INR)\\>1.7 or prothrombin time(PT)\\>15 s;\n19. Heparin treatment was received within 24 h;\n20. Thrombin inhibitors or factor Xa inhibitors were used within 48 h;\n21. Propensity for acute bleeding, including platelet counts of less than 100×109/ L or otherwise;\n22. Hereditary or acquired bleeding constitution;\n23. Onset with seizures;\n24. Severe liver and kidney dysfunction;\n25. Active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;\n26. Patients with anemia or polycythemia vera or other situations that require urgent oxygen inhalation;\n27. Patients with upper gastrointestinal bleeding or nausea or vomiting so that they cannot cooperate with the mask to inhale oxygen;\n28. Life expectancy \\< 1 year;\n29. Patients who could not complete the 90-day follow-up;\n30. Participation in other clinical trials within 3 months prior to screening;\n31. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Xunming Ji, MD. PhD","role":"CONTACT","phone":"+86010-83199430","email":"jixm@ccmu.edu.cn"},{"name":"Hetao Bian, MD.PhD","role":"CONTACT","phone":"+8618266806812","email":"hetaobian@163.com"}],"locations":[{"facility":"Xuan Wu Hospital，Capital Medical University","status":"RECRUITING","city":"Beijing","country":"China","contacts":[{"name":"Xunming Ji, MD. PhD","role":"CONTACT","phone":"861013120136877","email":"jixunming@vip.163.com"},{"name":"Xunming Ji, MD. PhD Xuanwu Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"},{"id":"D000018496","term":"Hyperoxia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"},{"id":"D000012818","term":"Signs and Symptoms, Respiratory"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M20290","name":"Hyperoxia","asFound":"Hyperoxia","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M15313","name":"Signs and Symptoms, Respiratory","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M4544","name":"Benzocaine","relevance":"LOW"},{"id":"T433","name":"Tannic Acid","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"Ot","name":"Other Dietary Supplements"}]}},"hasResults":false}